News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Seeking Alpha Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Cumberland Pharmaceuticals (NASDAQ:CPIX) reported a quarterly loss of $0.20 per share, missing analyst estimates. The company closed its Apotex transaction for $100 million and declared a special dividend of $1.50 per share, pivoting to focus on its ifetroban development pipeline. Despite the strategic shift …
Cumberland Pharmaceuticals announced a strategic shift in Q2 2026, selling its commercial brands to Apotex Health to transition into a biopharmaceutical development company. This transaction significantly strengthened its balance sheet with $100 million at closing and an estimated $108 million in total net proceeds, …
Earnings Call Insights: Cumberland Pharmaceuticals (CPIX) Q2 2026 MANAGEMENT VIEW * “In June, our shareholders overwhelmingly approved the strategic transaction with Apotex Health, on July 1st, we successfully closed the agreement to integrate our branded U.S. commercial businesses.” (Founder, Chairman, President & CEO A. …
Cumberland Pharmaceuticals (CPIX) reported a net loss of $4.1 million and net revenues of $166,458 for the second quarter of 2026, leading to a $0.27 loss per share. This follows a strategic transaction where Apotex Health acquired Cumberland’s FDA-approved brand portfolio for $100 million …
Cumberland Pharmaceuticals announced its Q2 2026 financial results and the completion of a $100 million strategic transaction with Apotex Health, involving the sale of its FDA-approved brands. Following this deal, Cumberland is transitioning to a development-stage biopharmaceutical company and has declared a special cash …
(RTTNews) - Today's top biotech gainers include Universe Pharmaceuticals, which recently filed its SEC report for the six months ended March 31, 2026; Cumberland Pharma, ahead of its second-quarter 2026 financial results due Tuesday; and Autolus Therapeutics, following the release of its preliminary quarterly …
This article lists ETFs that hold Cumberland Pharmaceuticals Inc. (CPIX) stocks, providing investors with options for more accessible and lower-risk investment opportunities. It highlights one specific ETF, the Bridgeway Ultra-Small Company Market ETF (BUSM), detailing its market value, weight in CPIX, management style, and …
Cumberland Pharmaceuticals (NASDAQ:CPIX) is set to go ex-dividend on August 3rd, 2026. The company will issue a special dividend of 1.5 USD per share. This information is crucial for investors interested in dividend capture strategies.
This article discusses the potential impact of proposed tariffs on imported generic drugs, which could reach 100-200%, and examines two microcap companies, Elite Pharmaceuticals (ELTP) and Cumberland Pharmaceuticals (CPIX), that might be affected. ELTP, a domestic manufacturer, could benefit from competitors facing tariffs, while …
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) announced it will provide a company update and its second-quarter 2026 financial results after the market closes on Tuesday, August 4, 2026. A conference call is scheduled for August 4 at 4:30 p.m. Eastern Time to discuss these results …
The article provides an institutional confidence score for Cumberland Pharmaceuticals Inc (CPIX), which currently stands at 3.00, ranking 92 out of 155 in the Pharmaceuticals industry. It highlights that the institutional shareholding proportion is 19.66%, a 30.06% decrease quarter-over-quarter. James Simons is identified as …
Cumberland Pharmaceuticals Inc (CPIX) has a financial score of 7.53, ranking 110 out of 155 in the pharmaceuticals industry, indicating stable financial status and high operating efficiency. Despite this, its latest quarterly revenue decreased by 22.04% year-over-year, and net profit saw a significant 361.69% …
Cumberland Pharmaceuticals Inc. will release its Q2 2026 financial results and provide a company update on August 4, 2026, after market close. A conference call is scheduled for 4:30 p.m. ET to discuss these results, with a replay available for one year. The company …
Cumberland Pharmaceuticals (Nasdaq: CPIX) announced it will release its Q2 2026 financial results and a company update on Tuesday, August 4, 2026, after market close, followed by a conference call. The Tennessee-based biopharmaceutical company is focused on rare diseases and is progressing its late-stage …
Cumberland Pharmaceuticals (CPIX) is expected to release its Q2 2026 earnings before the market opens on Tuesday, August 4th, with analysts forecasting a loss of $0.13 per share and revenue of $8.50 million. The company's previous quarter saw it meet loss estimates while exceeding …
This article details the shareholder structure of Cumberland Pharmaceuticals Inc (CPIX), outlining major individual and institutional holders. It provides a breakdown of shareholder types, institutional shareholding over several quarters, and recent shareholder activity with changes in holdings for key investors. The data includes the …
This article provides a revenue breakdown for Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), highlighting that the United States is the largest contributor to its revenue. In the last year, the U.S. accounted for $39.63 million USD, following $35.17 million USD the previous year. The data …
The article provides dividend and stock split information for Cumberland Pharmaceuticals Inc (CPIX). It states that the company has distributed $0.00 in dividends over the past five years and currently shows no specific dividend payment dates or ex-dividend dates. The current stock price for …
Cumberland Pharmaceuticals Inc. (CPIX) stock closed at $6.610, down 5.37%, with a market cap of $98.86 million. The company's fundamentals are considered healthy with high growth potential and a fairly valued assessment, ranking 102 out of 155 in the Pharmaceuticals industry. Analysts currently rate …
This article is a current report (8-K) filed by Cumberland Pharmaceuticals. The content indicates a document filing related to recent company events or financial updates.
This article compares two specialty pharmaceutical companies, Elite Pharmaceuticals (ELTP) and Cumberland Pharmaceuticals (CPIX), to determine which is a better investment. ELTP focuses on generic pharmaceuticals, expanding its product portfolio and manufacturing capacity, while CPIX is transforming into a development-focused biopharmaceutical company centered on …
Search by ticker symbol or company name and select a result to open its chart.